• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Black Diamond Therapeutics Inc.

    3/6/25 4:14:46 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BDTX alert in real time by email
    S-8 1 tm258269d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 6, 2025

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    BLACK DIAMOND THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

      Delaware 81-4254660  
     

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     
           
     

    One Main Street, 14th Floor

    Cambridge, Massachusetts

    02142  
      (Address of Principal Executive Offices) (Zip Code)  

     

    Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the “2020 Plan”)

    Black Diamond Therapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended (the “2020 ESPP”)

    (Full Title of the Plans)

     

     

    Mark A. Velleca, M.D., Ph.D.

    President and Chief Executive Officer

    Black Diamond Therapeutics, Inc.

    One Main Street, 14th Floor

    Cambridge, Massachusetts 02142

    (617) 252-0848

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Robert E. Puopolo, Esq.

    Marishka DeToy, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x  Smaller reporting company x
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is filed for the purposes of registering (i) an additional 2,265,786 shares of common stock, par value $0.0001 per share (the “common stock”), of Black Diamond Therapeutics, Inc. (the “Registrant”) that may be issued pursuant to the 2020 Plan and (ii) an additional 326,364 shares of common stock that may be issued pursuant to the 2020 ESPP. The number of shares of common stock reserved and available for issuance under the 2020 Plan is subject to an annual increase on each January 1 by an amount equal to the lesser of: (i) four percent (4%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) such lesser number of shares of common stock as determined by the Administrator (as defined in the 2020 Plan). Accordingly, on January 1, 2025, the number of shares of common stock reserved and available for issuance under the 2020 Plan increased by 2,265,786. This Registration Statement registers these additional 2,265,786 shares of common stock. The additional shares are of the same class as other securities relating to the 2020 Plan for which the Registrant’s registration statements filed on Form S-8 (File No. 333-236170, File No. 333-254686, File No. 333-263648, File No. 333-270393 and File No. 333-277834) filed with the Securities and Exchange Commission (the “SEC”) on January 30, 2020, March 25, 2021, March 17, 2022, March 9, 2023, and March 12, 2024, respectively, are effective. The number of shares of common stock reserved and available for issuance under the 2020 ESPP is subject to an annual increase on each January 1 by an amount equal to the least of (i) 326,364 shares of common stock, (ii) one percent (1%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the Administrator (as defined in the 2020 ESPP). Accordingly, on January 1, 2025, the number of shares of common stock reserved and available for issuance under the 2020 ESPP increased by 326,364. This Registration Statement registers these additional 326,364 shares of common stock. The additional shares are of the same class as other securities relating to the 2020 ESPP for which the Registrant’s registration statements filed on Form S-8 (File No. 333-236170, File No. 333-254686, File No. 333-263648, File No. 333-270393 and File No. 333-277834) filed with the SEC on January 30, 2020, March 25, 2021, March 17, 2022, March 9, 2023, and March 12, 2024 respectively, are effective. The information contained in the Registrant’s registration statements on Form S-8 (File No. 333-236170, File No. 333-254686, File No. 333-263648, File No. 333-270393 and File No. 333-277834) is hereby incorporated by reference pursuant to General Instruction E, except for “Item 8. Exhibits.”

     

     

     

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    See the Exhibit Index for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
       
    4.1   Fourth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-39200) filed on February 3, 2020)
         
    4.2   Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-39200) filed on June 6, 2024)
         
    4.2   Second Amended and Restated By-laws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant’s Annual Report on Form 10-K (File No. 001-39200) filed on March 12, 2024)
         
    4.3   Second Amended and Restated Investors’ Rights Agreement among the Registrant and certain of its stockholders, dated November 25, 2019 (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-235789) filed on January 3, 2020)
         
    4.4   Warrant to Purchase Stock, dated September 21, 2016, issued by the Registrant to Roche Finance Ltd (incorporated by reference to Exhibit 4.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-235789) filed on January 3, 2020)
         
    4.5   2020 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-235789) filed on January 21, 2020)
         
    4.6   2020 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.4 of the Registrant’s Annual Report on Form 10-K (File No. 001-39200) filed on March 12, 2024)
         
    5.1*   Opinion of Goodwin Procter LLP.
       
    23.1*   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
       
    23.2*   Consent of Goodwin Procter LLP (included in Exhibit 5.1).
       
    24.1*   Power of Attorney (included on signature page to this registration statement).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, State of Massachusetts, on the 6th day of March, 2025.

     

      BLACK DIAMOND THERAPEUTICS, INC.
         
      By: /s/ Mark A. Velleca
        Mark A. Velleca
    President and Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Mark A. Velleca and Brent Hatzis-Schoch, and each of them, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.

     

    Name   Title   Date
             
    /s/ Mark A. Velleca   President, Chief Executive Officer, Chairman and Director   March 6, 2025
    Mark A. Velleca   (Principal Executive Officer)    
             
    /s/ Erika Jones   Senior Vice President, Finance   March 6, 2025
    Erika Jones   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Ali Behbahani   Director   March 6, 2025
    Ali Behbahani        
             
    /s/ Kapil Dhingra   Director   March 6, 2025
    Kapil Dhingra        
             
    /s/ Shannon Campbell   Director   March 6, 2025
    Shannon Campbell        
             
    /s/ Prakash Raman   Director   March 6, 2025
    Prakash Raman        
             
    /s/ Samarth Kulkarni   Director   March 6, 2025
    Samarth Kulkarni        
             
    /s/ Garry E. Menzel   Director   March 6, 2025
    Garry E. Menzel        

     

     

    Get the next $BDTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDTX

    DatePrice TargetRatingAnalyst
    7/31/2024$20.00Outperform
    Raymond James
    7/14/2023Overweight
    Piper Sandler
    6/30/2023$2.00 → $10.00Hold → Buy
    Stifel
    6/28/2023$11.00Neutral → Buy
    H.C. Wainwright
    6/27/2023$10.00Neutral → Outperform
    Wedbush
    3/29/2022Outperform → Neutral
    Wedbush
    3/22/2022Buy → Neutral
    H.C. Wainwright
    9/30/2021$10.00Hold
    Stifel
    More analyst ratings

    $BDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Black Diamond Therapeutics with a new price target

      Raymond James initiated coverage of Black Diamond Therapeutics with a rating of Outperform and set a new price target of $20.00

      7/31/24 6:19:23 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Black Diamond Therapeutics

      Piper Sandler initiated coverage of Black Diamond Therapeutics with a rating of Overweight

      7/14/23 7:42:17 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Black Diamond Therapeutics from Hold to Buy and set a new price target of $10.00 from $2.00 previously

      6/30/23 7:17:14 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

      8/8/24 4:05:00 PM ET
      $BDTX
      $GYRE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Black Diamond Therapeutics Announces Changes to Board of Directors

      CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog

      4/11/24 8:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

      Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir

      11/6/23 7:45:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Black Diamond Therapeutics Inc.

      SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      11/14/24 1:28:32 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Black Diamond Therapeutics Inc.

      SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      11/14/24 12:02:05 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc.

      SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      8/8/24 4:48:56 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Growth N V bought $934,080 worth of shares (400,000 units at $2.34), increasing direct ownership by 5% to 8,517,839 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      10/19/23 3:08:35 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: 24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, April 7, 2025Stifel 2025 Virtual Targeted Oncology Forum fireside chat at 1:00pm ET on Tuesday, April 8, 2025 Webcasts will be available at the start of the presentations on the investor rel

      3/31/25 8:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

      The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancerBlack Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a

      3/19/25 7:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored "window of opportunity" trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 2025Cash, cash equivalents, and investments of $98.6 million as of December 31, 2024, expected to be sufficient to fund operations into Q4 2026 CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter an

      3/6/25 4:01:00 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Financials

    Live finance-specific insights

    See more
    • Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

      BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations Confirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable diseaseExpansion cohorts expected to commence i

      6/27/23 7:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Black Diamond Therapeutics Inc.

      DEFA14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

      4/18/25 4:05:01 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Black Diamond Therapeutics Inc.

      DEF 14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

      4/18/25 4:01:26 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Black Diamond Therapeutics Inc.

      SCHEDULE 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      3/21/25 1:01:32 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Behbahani Ali was granted 7,646 shares, increasing direct ownership by 12% to 70,980 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/21/25 4:19:30 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Raman Prakash was granted 6,848 shares, increasing direct ownership by 68% to 16,993 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/21/25 4:04:02 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Biotech Growth N V sold $11,997,749 worth of shares (5,784,292 units at $2.07), decreasing direct ownership by 68% to 2,733,547 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/20/25 9:01:40 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care